Author:
Lübbers Katharina,Pavlychenko Mykola,Wald Theresa,Wiegand Susanne,Dietz Andreas,Zebralla Veit,Wichmann Gunnar
Abstract
BackgroundThe landmark EXTREME trial established cisplatin, 5-fluorouracil and cetuximab (PFE) as first-line chemotherapy (1L-ChT) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). We were interested in outcome differences of R/M HNSCC in 1L-ChT and factors influencing outcome in certain subgroups, especially patients receiving PFE, and the value of PFE compared to other 1L-ChT regimens to provide real world evidence (RWE).MethodsFor this retrospective monocentric study, 124 R/M HNSCC patients without curative surgical or radiotherapy options receiving at least one cycle of 1L-ChT were eligible. We analyzed their outcome using Kaplan-Meier plot and Cox regression to identify predictors for prolonged survival.ResultsSubgroups benefiting significantly from PFE were patients suffering from an index HNSCC outside the oropharynx. The PFE regimen proved to be superior to all other 1L-ChT regimens in clinical routine. Significant outcome differences between PFE treatment within or outside controlled trials were not seen.ConclusionThis retrospective analysis provides RWE for factors linked to improved outcome. Subgroup analyses highlight the lasting value of PFE among the growing spectrum of 1L-ChT. Importantly, fit smokers with high level alcohol consumption benefit from PFE; considering the patient’s lifestyle factors, PFE should not be ignored in decision-making.
Reference28 articles.
1. Prognoses and Improvement for Head and Neck Cancers Diagnosed in Europe in Early 2000s: The EUROCARE-5 Population-Based Study;Gatta;Eur J Cancer,2015
2. NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018;Colevas;J Natl Compr Canc Netw,2018
3. Platinum-Based Chemotherapy Plus Cetuximab in Head and Neck Cancer;Vermorken;N Engl J Med,2008
4. Pembrolizumab Alone or With Chemotherapy Versus Cetuximab With Chemotherapy for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (KEYNOTE-048): A Randomised, Open-Label, Phase 3 Study;Burtness;Lancet,2019
5. Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology;Pfister;J Natl Compr Canc Netw,2020